antimalari
drug
chloroquin
suggest
treatment
ebola
viru
infect
chloroquin
inhibit
viru
replic
vitro
cytotox
concentr
mous
hamster
model
treatment
improv
surviv
chloroquin
promis
treatment
ebola
effort
direct
toward
drug
class
c
hloroquin
first
use
antimalari
drug
widespread
resist
plasmodium
falciparum
strain
emerg
howev
year
drug
also
recogn
broadspectrum
antivir
properti
includ
activ
human
coronavirus
sever
acut
respiratori
syndrom
coronaviru
dengu
viru
chikungunya
viru
influenza
viru
cell
cultur
despit
data
chloroquin
approv
use
viral
infect
previou
vitro
data
state
half
maxim
effect
concentr
ec
ec
chloroquin
ebola
viru
ebov
respect
twice
daili
dose
mgkg
intraperiton
rapidli
achiev
steadyst
concentr
blood
mice
dose
regimen
result
surviv
mice
infect
mouseadapt
ebov
data
led
suggest
chloroquin
deriv
use
person
ebov
infect
drug
approv
use
human
extens
safeti
profil
inexpens
determin
whether
protect
would
extend
ebov
hamster
model
investig
chloroquin
treatment
model
attempt
repeat
previou
vitro
find
find
mous
model
vero
cell
infect
focusform
unit
ebov
express
enhanc
green
fluoresc
protein
incub
inoculum
remov
replac
media
dulbecco
modifi
eagl
medium
fetal
bovin
serum
pennstrep
lglutamin
contain
chloroquin
sigma
st
loui
mo
usa
supernat
collect
day
infect
media
replac
fresh
drug
viral
rna
extract
supernat
quantifi
realtim
quantit
revers
transcript
pcr
previous
describ
concurr
cell
viabil
assay
use
cell
aqueou
one
solut
promega
madison
wi
usa
accord
manufactur
instruct
ec
determin
use
graphpad
softwar
san
diego
ca
usa
ad
h
infect
chloroquin
ml
reduc
viral
load
log
respect
peak
reduct
observ
day
without
signific
cytotox
figur
analysi
data
day
result
ec
ec
concentr
compar
previou
data
howev
reduct
viral
load
concentr
time
point
neglig
although
concentr
chloroquin
reduc
viral
load
log
start
day
decreas
accompani
high
level
cytotox
evid
cytotox
assay
microscop
result
poor
select
chloroquin
sixweekold
balbc
mice
syrian
hamster
harlan
indianapoli
usa
inocul
intraperiton
lethal
dose
ebov
mous
hamster
wellestablish
diseas
model
ebov
infect
treatment
initi
h
inocul
treatment
group
mice
hamster
receiv
mgkg
chloroquin
alon
intraperiton
vehicl
group
receiv
equival
volum
steril
salin
intraperiton
mockinfect
anim
receiv
steril
tissu
cultur
media
place
ebov
addit
group
hamster
receiv
mgkg
chloroquin
intraperiton
everi
h
combin
mgkg
doxycyclin
gavag
everi
h
mg
kg
azithromycin
intraperiton
everi
h
inocul
anim
monitor
least
twice
daili
euthan
use
human
endpoint
score
criteria
approv
anim
care
use
committe
rocki
mountain
laboratori
hamilton
mt
usa
analysi
surviv
perform
graphpad
two
mockchalleng
mice
surviv
chloroquin
mgkg
treatment
alon
figur
panel
mice
infect
ebov
treat
chloroquin
surviv
mice
infect
ebov
treat
vehicl
surviv
median
surviv
mockchallengedchloroquinetr
mice
ebovinfectedchloroquinetr
mice
ebovinfectedvehicletr
mice
respect
treatment
signific
effect
surviv
dose
although
previous
state
maximum
toler
dose
mice
well
toler
anim
studi
clearli
improv
surviv
anim
challeng
ebov
dose
mgkg
chloroquin
given
hamster
challeng
ebov
studi
termin
day
treatment
nearli
treat
anim
ebov
mockchalleng
group
die
acut
toxic
administr
chloroquin
intraperiton
typic
within
min
treatment
figur
panel
b
separ
studi
hamster
treat
chloroquin
mgkg
combin
doxycyclin
mgkg
azithromycin
mgkg
addit
provid
broadspectrum
antimicrobi
drug
coverag
reperfus
injuri
gut
ebov
diseas
would
subsequ
result
bacteri
sepsi
suspect
possibl
caus
death
thu
broadspectrum
antimicrobi
drug
propos
help
regard
studi
toxic
observ
mockchalleng
group
result
combin
treatment
find
suggest
hamster
toler
dose
chloroquin
howev
treatment
effect
surviv
combinationtr
vehicletr
group
surviv
median
surviv
time
compar
figur
panel
c
despit
activ
chloroquin
ebov
vitro
observ
benefit
administr
mous
hamster
model
mous
model
dose
mg
kg
result
toxic
alter
surviv
therefor
higher
concentr
chloroquin
mous
would
expect
possibl
hamster
dose
alreadi
lethal
hamster
model
lower
dose
mgkg
combin
doxycyclin
azithromycinwhich
togeth
provid
broadspectrum
antimicrobi
coverag
addit
doxycyclin
small
antivir
effect
ebovsurviv
chang
previou
anecdot
report
incident
use
chloroquin
patient
filoviru
infect
also
support
benefit
use
togeth
data
suggest
chloroquin
unlik
provid
protect
ebov
infect
human
given
vitro
activ
mani
differ
virus
longstand
use
human
chloroquin
put
multipl
clinic
trial
dengu
viru
infect
viremia
decreas
chloroquin
neither
prevent
influenza
viru
infect
improv
outcom
chikungunya
viru
infect
despit
promis
vitro
activ
virus
taken
togeth
previou
find
less
pathogen
virus
clinic
use
chloroquin
seem
unlik
provid
benefit
either
prophylaxi
treatment
ebov
moreov
chloroquin
small
therapeut
window
dose
treatment
acut
malaria
mgkg
lethal
start
mgkg
thu
current
preclin
data
support
continu
consider
chloroquin
use
ebov
infect
human
